Will polygenic risk scores for cancer ever be clinically useful?

Código QR

Will polygenic risk scores for cancer ever be clinically useful?

Guardado en:

Detalles Bibliográficos
Autores principales:	Amit Sud, Clare Turnbull, Richard Houlston
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6b66d916c4b344f59a4dc34e712c70a3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease
por: Andrew Bakshi, et al.
Publicado: (2021)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Alissa Visram, et al.
Publicado: (2021)

Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score
por: Soonmyung Paik, et al.
Publicado: (2021)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Brock Schroeder, et al.
Publicado: (2017)

Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes
por: James B. Studd, et al.
Publicado: (2021)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Richard Buus, et al.
Publicado: (2021)

Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
por: Della Makower, et al.
Publicado: (2021)

Serum calcium levels, TRPM7, TRPC1, microcalcifications, and breast cancer using breast imaging reporting and data system scores
por: Mandavilli S, et al.
Publicado: (2012)

How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies
por: Xinran Wang, et al.
Publicado: (2021)

Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
por: Laura Duran-Lozano, et al.
Publicado: (2021)

The clinical and molecular significance associated with STING signaling in breast cancer
por: Eileen E. Parkes, et al.
Publicado: (2021)

Tamoxifen for women at high risk of breast cancer
por: Nazarali SA, et al.
Publicado: (2014)

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
por: Fenil Shah, et al.
Publicado: (2017)

Rare deleterious germline variants and risk of lung cancer
por: Yanhong Liu, et al.
Publicado: (2021)

Cardiac risk in the treatment of breast cancer: assessment and management
por: Valachis A, et al.
Publicado: (2015)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Yang Hu, et al.
Publicado: (2021)

Decreased risk of breast cancer associated with oral bisphosphonate therapy
por: Mathew A, et al.
Publicado: (2012)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
por: Amaia Lujambio, et al.
Publicado: (2021)

Potential clinical applications of halichondrins in breast cancer and other neoplasms
por: Ortega V, et al.
Publicado: (2012)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
por: Dirk Schadendorf, et al.
Publicado: (2021)

The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk
por: Thomas P. Slavin, et al.
Publicado: (2017)

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
por: Jane Bayani, et al.
Publicado: (2021)

Clinical application of a lung cancer organoid (tumoroid) culture system
por: Etsuko Yokota, et al.
Publicado: (2021)

Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
por: Saksena R, et al.
Publicado: (2013)

MET targeted therapy for lung cancer: clinical development and future directions
por: Feng Y, et al.
Publicado: (2012)

Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy
por: Sung Uk Lee MD, et al.
Publicado: (2021)

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
por: Vogel VG
Publicado: (2011)

EGFR may couple moderate alcohol consumption to increased breast cancer risk
por: Christopher P Mill, et al.
Publicado: (2009)

Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery
por: Sankha S. Basu, et al.
Publicado: (2021)

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
por: Anthony Goncalves, et al.
Publicado: (2021)

Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry
por: Yash S. Huilgol, et al.
Publicado: (2021)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)

Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes
por: Martei YM, et al.
Publicado: (2015)

Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study
por: Anna-Karin Wennstig, et al.
Publicado: (2021)

Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge
por: Grace G. Bushnell, et al.
Publicado: (2021)

Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Publicado: (2021)

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants
por: Matteo Lambertini, et al.
Publicado: (2021)

A functionally significant SNP in TP53 and breast cancer risk in African-American women
por: Maureen E. Murphy, et al.
Publicado: (2017)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Ye-Jee Kim, et al.
Publicado: (2021)

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
por: Xi Jiao, et al.
Publicado: (2021)